Evaluating the Safety and Immune Response to a Respiratory Syncytial Virus (RSV) Vaccine in Adults, RSV-Seropositive Children, and RSV-Seronegative Infants and Children
Completed · Phase 1 · Has a placebo group
Conditions studied: Respiratory Syncytial Virus Infections
In brief
Human respiratory syncytial virus (RSV) is a common cause of upper respiratory tract illnesses as well as more severe lower respiratory illnesses, including bronchiolitis and pneumonia. RSV affects almost all children within the first 2 years of life. This study will evaluate the safety and immune response to the RSV MEDI ΔM2-2 vaccine among adults, RSV-seropositive children, and RSV-seronegative infants and children.
Key facts
- Study ID
- NCT01459198
- Run by
- National Institute of Allergy and Infectious Diseases (NIAID)
- People needed
- 60
- Starts
- 2011-08-01
- Expected to finish
- 2015-08-01
- Last updated by the study team
- 2015-12-15
Who can join
Age: 1 and older, up to 49. Sex: any. Healthy volunteers: accepted.
Where it is running
- John Hopkins Center for Immunization Research — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.